TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipsychotic Polypharmacy in Schizophrenia
Brief Summary: The literature suggests that when a patient is prescribed more than one antipsychotic for at least 30 days, he or she is likely to continue on that combination. In this 12 week study 100 adult patients being treated on more than one antipsychotic medication for at least 30 days will be recruited. In order to control for the natural course of the illness, patients will be randomly assigned to one of two groups: the first group will continue the second medication hidden in a capsule at the same dose, while the second group will be given an inactive capsule (placebo) - the capsules in both group will be identical such that neither the patient nor the treating doctor will be able to identify the group assignment.


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: main antipsychotic medication and placebo | Intervention Type: DRUG; Name: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: main antipsychotic medication and placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
Brief Summary: There are worrying signs that parasitological responses to the artemisinin drugs for uncomplicated falciparum malaria are slower than elsewhere in the world.If responses to artesunate are poor it is essential to have characterised the blood concentration profile as well as the parasitological response to differentiate resistance from abnormal pharmacokinetics.

The primary objective of the study is to assess the level of resistance to artemisinin derivatives in Western Cambodia.

A detailed evaluation of 2 different artesunate containing regimens in patients with uncomplicated malaria will be performed. Patients will be randomised to receive either a) Artesunate 2mg/kg/day for 7 days or b) Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4 The effect on parasite clearance and cure will be assessed in relation to blood concentrations of the antimalarial drugs ('PK-PD').


Options:
A: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
B: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
C: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
D: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
Brief Summary: There are worrying signs that parasitological responses to the artemisinin drugs for uncomplicated falciparum malaria are slower than elsewhere in the world.If responses to artesunate are poor it is essential to have characterised the blood concentration profile as well as the parasitological response to differentiate resistance from abnormal pharmacokinetics.

The primary objective of the study is to assess the level of resistance to artemisinin derivatives in Western Cambodia.

A detailed evaluation of 2 different artesunate containing regimens in patients with uncomplicated malaria will be performed. Patients will be randomised to receive either a) Artesunate 2mg/kg/day for 7 days or b) Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4 The effect on parasite clearance and cure will be assessed in relation to blood concentrations of the antimalarial drugs ('PK-PD').


Options:
A: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem® (artemether lumefantrine) | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: Coartem® (artemether lumefantrine); Assigned to Arm(s): AL group
C: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
D: Arm Label: Pyramax; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): Pyramax

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
Brief Summary: There are worrying signs that parasitological responses to the artemisinin drugs for uncomplicated falciparum malaria are slower than elsewhere in the world.If responses to artesunate are poor it is essential to have characterised the blood concentration profile as well as the parasitological response to differentiate resistance from abnormal pharmacokinetics.

The primary objective of the study is to assess the level of resistance to artemisinin derivatives in Western Cambodia.

A detailed evaluation of 2 different artesunate containing regimens in patients with uncomplicated malaria will be performed. Patients will be randomised to receive either a) Artesunate 2mg/kg/day for 7 days or b) Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4 The effect on parasite clearance and cure will be assessed in relation to blood concentrations of the antimalarial drugs ('PK-PD').


Options:
A: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine + artesunate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A
C: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
D: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana
Brief Summary: 1) To compare in a setting where microscopy for malaria is available whether introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v microscopy). 2) To compare whether, in a setting where microscopy for malaria is not available, introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v clinical diagnosis).


Options:
A: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana
Brief Summary: 1) To compare in a setting where microscopy for malaria is available whether introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v microscopy). 2) To compare whether, in a setting where microscopy for malaria is not available, introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v clinical diagnosis).


Options:
A: Arm Label: RDT+ACT group; Type: EXPERIMENTAL; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Arm Label: Clinical judgement+ACT group; Type: ACTIVE_COMPARATOR; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Intervention Type: DEVICE; Name: RDT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group | Intervention Type: OTHER; Name: Clinical Judgement as basis for treatment of malaria with ACT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3
C: Arm Label: Observation; Type: N/A; Interventions: Drug: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam) | Intervention Type: DRUG; Name: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam); Assigned to Arm(s): Observation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Clinical algorithm and microscopy diagnosis of malaria | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Clinical algorithm and microscopy diagnosis of malaria; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana
Brief Summary: 1) To compare in a setting where microscopy for malaria is available whether introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v microscopy). 2) To compare whether, in a setting where microscopy for malaria is not available, introducing rapid diagnostic tests (RDTs) improves targetting of antimalarial drugs and antibiotics (RDT v clinical diagnosis).


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Microscopy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clinical diagnosis for malaria | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Rapid diagnostic test | Intervention Type: PROCEDURE; Name: Rapid diagnostic test; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Microscopy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Clinical diagnosis for malaria; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Provision of antimalarial treatment at home; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study
Brief Summary: Coronary heart disease (CHD) is the leading cause of death in the United States, but fewer than half of all individuals at risk for CHD take advantage of proven strategies to lower their chances of developing this disease. This study will assess the effectiveness of Heart to Heart, a Web-based program, at educating people on ways to incorporate CHD risk-reduction strategies into their lives.


Options:
A: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: video | Intervention Type: OTHER; Name: video; Assigned to Arm(s): 2
C: Arm Label: Decision Aid Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Aid Tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Decision Aid Tool; Assigned to Arm(s): Decision Aid Tool | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study
Brief Summary: Coronary heart disease (CHD) is the leading cause of death in the United States, but fewer than half of all individuals at risk for CHD take advantage of proven strategies to lower their chances of developing this disease. This study will assess the effectiveness of Heart to Heart, a Web-based program, at educating people on ways to incorporate CHD risk-reduction strategies into their lives.


Options:
A: Arm Label: One-on-one counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Arm Label: Web counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle and medication intervention; Assigned to Arm(s): One-on-one counseling, Web counseling
B: Intervention Type: BEHAVIORAL; Name: Internet-based tailored advice on cardiovascular risk; Assigned to Arm(s): N/A
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study
Brief Summary: Coronary heart disease (CHD) is the leading cause of death in the United States, but fewer than half of all individuals at risk for CHD take advantage of proven strategies to lower their chances of developing this disease. This study will assess the effectiveness of Heart to Heart, a Web-based program, at educating people on ways to incorporate CHD risk-reduction strategies into their lives.


Options:
A: Arm Label: Rapid genetic counseling; Type: EXPERIMENTAL; Interventions: Behavioral: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling intervention; Assigned to Arm(s): Rapid genetic counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Rapid genetic counseling | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): Rapid genetic counseling
B: Arm Label: Using Power Up; Type: EXPERIMENTAL; Interventions: Behavioral: Shared Decision Making tool | Arm Label: Not using Power Up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making tool; Assigned to Arm(s): Using Power Up
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
D: Arm Label: Traditional CERSG Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Health Worker Diabetes Education: Print media | Arm Label: Web-Based Materials Arm; Type: EXPERIMENTAL; Interventions: Behavioral: CHW Diabetes Education: tailored web site | Intervention Type: BEHAVIORAL; Name: Community Health Worker Diabetes Education: Print media; Assigned to Arm(s): Traditional CERSG Arm | Intervention Type: BEHAVIORAL; Name: CHW Diabetes Education: tailored web site; Assigned to Arm(s): Web-Based Materials Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study
Brief Summary: Coronary heart disease (CHD) is the leading cause of death in the United States, but fewer than half of all individuals at risk for CHD take advantage of proven strategies to lower their chances of developing this disease. This study will assess the effectiveness of Heart to Heart, a Web-based program, at educating people on ways to incorporate CHD risk-reduction strategies into their lives.


Options:
A: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stepping Up to Health | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Up to Health | Intervention Type: BEHAVIORAL; Name: Stepping Up to Health; Assigned to Arm(s): 1, 2
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group I; Type: EXPERIMENTAL; Interventions: Behavioral: self-regulation | Intervention Type: BEHAVIORAL; Name: self-regulation; Assigned to Arm(s): Intervention Group I

Answer: B